Sang Mee Lee

Title: Innovations of Sang Mee Lee

Introduction

Sang Mee Lee is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human growth hormones and alpha-1 antitrypsin variants. With a total of three patents to his name, his work has the potential to impact medical treatments and therapies.

Latest Patents

One of his latest patents is a method of purifying a long-acting human growth hormone. This invention relates to the NexP-hGH protein and its production method, which involves a specific isoform that enhances long-acting properties in vivo. The purification method includes several steps, such as anion-exchange resin chromatography, hydrophobic resin chromatography, and affinity chromatography, ensuring high purity of the NexP-hGH. Another significant patent involves a novel alpha-1 antitrypsin variant, which boasts excellent stability in the body and maintains an inhibitory effect on elastase activities. This variant is particularly useful in preventing or treating alpha-1 antitrypsin deficiency.

Career Highlights

Sang Mee Lee has worked with prominent companies in the biotechnology sector, including Alteogen, Inc. and CJ Healthcare Corporation. His experience in these organizations has allowed him to collaborate on various innovative projects that advance medical science.

Collaborations

Some of his notable coworkers include Hye-Shin Chung and Soon Jae Park. Their collaborative efforts have contributed to the success of the projects they have undertaken together.

Conclusion

Sang Mee Lee's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in medical treatments and therapies.